Staten Island, NY, United States of America

Raja Krishnaswami

This inventor holds 1 USPTO granted patent. Top assignee: The City University of New York. Active years: 2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Raja Krishnaswami. Retrieved from https://idiyas.com/inventor/raja-krishnaswami

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Raja Krishnaswami in Cancer Research

Introduction

Raja Krishnaswami is an accomplished inventor based in Staten Island, NY (US). He has made significant contributions to the field of cancer research through his innovative work on curcumin derivatives. His research focuses on developing effective anti-cancer agents that can inhibit tumor growth.

Latest Patents

Raja Krishnaswami holds a patent for "Curcumin-antibody conjugates as anti-cancer agents." This invention relates to curcumin derivatives characterized by a specific formula. The derivatives are designed to bind to target antigens of tumor cells, providing a method for inhibiting tumor growth in humans. The patent outlines the structure of the curcumin derivatives and the methods for their production and application.

Career Highlights

Raja Krishnaswami is affiliated with The City University of New York, where he continues to advance his research in cancer therapeutics. His work has garnered attention for its potential impact on cancer treatment and patient outcomes.

Collaborations

Raja collaborates with Probal Banerjee, who is also involved in cancer research. Their partnership enhances the scope and depth of their research initiatives.

Conclusion

Raja Krishnaswami's innovative work in developing curcumin-based anti-cancer agents represents a significant advancement in cancer research. His contributions have the potential to improve treatment options for patients facing this challenging disease.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…